J
Jason Katz
Researcher at Celgene
Publications - 7
Citations - 248
Jason Katz is an academic researcher from Celgene. The author has contributed to research in topics: Kinase & Aminopurine. The author has an hindex of 5, co-authored 7 publications receiving 197 citations.
Papers
More filters
Journal ArticleDOI
Discovery of CC-930, an orally active anti-fibrotic JNK inhibitor.
Veronique Plantevin Krenitsky,Lisa Nadolny,Mercedes Delgado,Leticia Ayala,Steven S. Clareen,Robert Hilgraf,Ronald Albers,Sayee G. Hegde,Neil R. D'sidocky,John Sapienza,Jonathan Wright,Meg Mccarrick,Sogole Bahmanyar,Philip P Chamberlain,Silvia L. Delker,Jeff Muir,David Giegel,Li Xu,Maria Celeridad,Jeff Lachowitzer,Brydon L. Bennett,Mehran F. Moghaddam,Oleg Khatsenko,Jason Katz,Rachel Fan,April Bai,Yang Tang,Michael A. Shirley,Brent Benish,Tracey Bodine,Kate Blease,Heather Raymon,Brian E. Cathers,Yoshitaka Satoh +33 more
TL;DR: This Letter describes the discovery of potent, selective, and orally active aminopurine JNK inhibitors and the identification of 1 (CC-930) as a development candidate, which is currently in Phase II clinical trial for IPF.
Journal ArticleDOI
Pomalidomide Shows Significant Therapeutic Activity against CNS Lymphoma with a Major Impact on the Tumor Microenvironment in Murine Models
Zhimin Li,Yushi Qiu,David Personett,Peng Huang,Brandy Edenfield,Jason Katz,Darius Babusis,Yang Tang,Michael A. Shirely,Mehran F. Moghaddam,John A. Copland,Han W. Tun +11 more
TL;DR: POM is a promising therapeutic agent for CNS lymphoma with excellent CNS penetration, significant preclinical therapeutic activity, and a major impact on the tumor microenvironment.
Journal ArticleDOI
The Discovery of a Dual TTK Protein Kinase/CDC2-Like Kinase (CLK2) Inhibitor for the Treatment of Triple Negative Breast Cancer Initiated from a Phenotypic Screen
Jennifer Riggs,Nagy Mark A,Jan Elsner,Paul Erdman,Dan Cashion,Dale Robinson,Roy L. Harris,Dehua Huang,Lida Tehrani,Gordafaried Deyanat-Yazdi,Rama K. Narla,Xiaohui Peng,Tam Tran,Leo Barnes,Terra Miller,Jason Katz,Yang Tang,Ming Chen,Mehran F. Moghaddam,Sogole Bahmanyar,Barbra Pagarigan,Silvia L. Delker,Laurie LeBrun,Philip P Chamberlain,Andrew Antony Calabrese,Stacie S. Canan,Katerina Leftheris,Dan Zhu,John F. Boylan +28 more
TL;DR: The synthesis and structure-activity relationship (SAR) of a novel series of 2,4,5-trisubstituted-7H-pyrrolo[2,3-d]pyrimidines with potent activity against TNBC tumor cell lines supported the nomination of CC-671 into IND-enabling studies as a single agent TNBC therapy.
Journal ArticleDOI
Aminopurine based JNK inhibitors for the prevention of ischemia reperfusion injury.
Veronique Plantevin Krenitsky,Mercedes Delgado,Lisa Nadolny,Kiran Sahasrabudhe,Leticia Ayala,Steven S. Clareen,Robert Hilgraf,Ronald Albers,Adam Kois,Kevin S. Hughes,Jonathan Wright,Jacek Nowakowski,Elise Sudbeck,Sutapa Ghosh,Sogole Bahmanyar,Philip P Chamberlain,Jeff Muir,Brian E. Cathers,David Giegel,Li Xu,Maria Celeridad,Mehran F. Moghaddam,Oleg Khatsenko,Paul Omholt,Jason Katz,Sema Pai,Rachel Fan,Yang Tang,Michael A. Shirley,Brent Benish,Kate Blease,Heather Raymon,Shripad S. Bhagwat,Henderson Ian,Andrew G. Cole,Brydon L. Bennett,Yoshitaka Satoh +36 more
TL;DR: This Letter describes the optimization of an aminopurine lead with modest potency and poor overall kinase selectivity which led to the identification of a series of potent, selective JNK inhibitors.
Journal ArticleDOI
Discovery and optimization of thieno[2,3-d]pyrimidines as B-Raf inhibitors.
Garrick Packard,Patrick Papa,Jennifer Riggs,Paul Erdman,Lida Tehrani,Dale Robinson,Roy L. Harris,Graziella I. Shevlin,Sophie Perrin-Ninkovic,Robert Hilgraf,Margaret A. Mccarrick,Tam Tran,Yuedi W. Fleming,April Bai,Samantha J. Richardson,Jason Katz,Yang Tang,Jim Leisten,Mehran F. Moghaddam,Brian E. Cathers,Dan Zhu,Sakata Steven T +21 more
TL;DR: Thieno[2,3-d]pyrimidines is identified as a core scaffold of small molecule B-Raf inhibitors and the SAR of analogs in this series will be described.